Thus, these data collectively demonstrate that the inherited TME vascular heterogeneity between the SSIL2Rγ- (DLL4-high) and SS.BN3IL2Rγ- (DLL4-low) rats 24-26 strongly modifies the therapeutic efficacy of PTT with TNPs, despite the implanted triple negative breast cancer cells being identical. This evidence concerns the gene DLL4 and triple-negative breast carcinoma.